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HORMESIS PERVASIVENESS AND ITS POTENTIAL IMPLICATIONS FOR
PHARMACEUTICAL RESEARCH AND DEVELOPMENT
Kenneth I. Maynard  Sanofi US, Inc.
 This mini-review illustrates that hormesis is not only confined to the areas of bio-
chemistry, radiation biology and toxicology, where it is traditionally known, but illustrates,
by citing published scientific literature, that it is found across a wide range of biomedical
science and clinical medicine such as neuroscience, cardiology and oncology. The use of
techniques and technology, including high through-put screening, micro-dosing or phase
0 studies, pharmacometrics and adaptive trial design in the clinic, are proposed to illus-
trate how acknowledging the potential impact of hormesis throughout different stages of
drug discovery and development, including hurdles related to efficacy and safety, could
help the pharmaceutical industry address some of its major and frequently mentioned
challenges.
Keywords: dose response, hormesis, drug discovery, drug development, research and development,
pharmaceutical industry
1. HORMESIS IS PERVASIVE ACROSS SCIENCE AND MEDICINE
Traditionally, hormesis was confined to the areas of biochemistry,
radiation biology and toxicology. Over the past twelve years, however, the
publication of J-, U- or inverted U-shaped dose-response curves has
exploded illustrating the presence of hormesis across many fields of bio-
logical sciences and clinical medicine.
The volume of literature published in this area each year has grown 10-
fold in large part due to single, original papers in a variety of high impact
factor, scientific, peer-reviewed international journals, but also due to
entire volumes of journals which have been devoted to hormesis. Some of
the various areas include aging, benign prostate enlargement, biochemical
and physiological cellular responses, caloric restriction, cardiovascular
function, cancer and tumor development, chemo-sensitization, chemother-
apy, dermatology, drug binding, hair growth, sexual dysfunction, ocular dis-
eases, osteoporosis, oxidative stress, prion diseases and synaptic plasticity
(Calabrese 2008a, Maynard et al. 2008). Four special volumes concentrated
on neuroscience, including neuronal survival, neurite outgrowth, glial
adaptive responses to neurotoxins, p-glycoprotein efflux transporter activi-
ty, anxiety and anxiolytic drugs, epilepsy, traumatic brain injury, stroke,
addiction, memory and Alzheimer’s Disease (Calabrese 2008b).
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The examples below illustrate the caliber of scientific inquiry and
diversity of disciplines where hormesis is exemplified across a broad
range of biological science and clinical medicine.
2. SPECIFIC EXAMPLES OF HORMESIS
2.1 Neuroprotection
Since 1999 a series of original papers have been published in various
journals and from various laboratories showing that nicotinamide (NAm,
vitamin B3) is neuroprotective in models of stroke. U-shaped dose-
response neuroprotection as shown by reduction in cerebral infarction
volume was found in a model of focal cerebral ischemia using permanent
middle cerebral artery occlusion in male Wistar rats at 500 mg/kg NAm,
but not at 50 mg/kg or 1000 mg/kg (Ayoub et al. 1999). In separate stud-
ies, NAm was also shown to be neuroprotective in a model of transient
middle cerebral artery occlusion, in female Wistar and Sprague Dawley
rats (Sakakibara et al. 2000) as well as in Fischer 344 control and diabetic
rats (Sakakibara et al. 2002).
From a rigorously scientific perspective, what is convincing about the
NAm-induced hormetic response with regard to the neuroprotection is
its consistency across different strains of both male and female rats and
mice, different models of stroke and original studies published from dif-
ferent laboratories, each consistently showing the U-shaped neuroprotec-
tive effect of NAm.
NAm is a poly-ADP ribose polymerase (PARP) inhibitor and other
PARP inhibitors such as 3-aminobenzamide exhibit U-shaped neuropro-
tection (Ayoub et al. 1999). PARP activation leads to the repair of DNA
damage, which may be caused by ischemia. However, excessive PARP acti-
vation leads to neuronal injury through augmentation of nitric oxide (NO)
- and glutamate-induced excitotoxicity and depleted energy (ATP) there-
fore adding insult to injury, since it is the initial energy imbalance that ini-
tiates the various ischemic cascades leading to neuronal and glial cell
death. It was therefore speculated by Ayoub and colleagues (Ayoub et al.
1999) that the U-shaped dose-response curve may have been due to opti-
mal PARP regulation. A review of the literature at that time, 1999 – 2001,
revealed U-shaped dose-response neuroprotection reported not only by
PARP inhibitors, but by a variety of agents representing many potential neu-
roprotective mechanisms (Table 1). Thus, it is true to say that at least in
models of cerebral infarction, but perhaps in other models of central nerv-
ous system injury as well, the hormetic protection illustrated by reduction
in cerebral infarction volume transcends a wide variety of mechanisms of
action, and may perhaps point to a more generalized phenomenon, which
is not yet currently understood. This is further evidenced by a later review
of dose-response features of neuroprotective agents (Calabrese 2008c).
K. I. Maynard
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2.2 Chronic Heart Failure
In the 1990s, there was a major turn around of our understanding of
the usefulness of beta-adrenoceptor blockers in the treatment of chronic
heart failure (CHF). Beta-adrenoceptor blockers were originally contra-
indicated in the treatment of CHF until it was understood that the initial
negative agonistic ionotropic effect was transient, eventually to be
reversed, leading to improvement of CHF symptoms.
Agonists of beta-2-adrenoceptors acutely activate the receptor result-
ing in a reduction in the cardiac output. However, chronic treatment with
inverse agonists such as metoprolol and carvedilol, have been shown in
clinical trials to lead to improvement of cardiac output and a reduction
in mortality. It is believed that this reciprocity due to receptor desensiti-
zation is the mechanism of action accounting for the temporal hormesis
observed with selective beta-2-adrenoceptor inverse agonists (Dudekula et
al. 2005). In this case, the hormetic effect is not due to a concentra-
tion/dose effect, but based on the duration of exposure to the drug
which leads to the reversal of the initial drug response over time with
chronic treatment.
2.3 Angiogenesis and Tumor Growth
The pharmacology of a 5 amino acid, anti-angiogenic peptide, ATN-
161, which binds to integrins has been shown to illustrate U-shaped dose-
response curves in various models of angiogenesis and tumor growth
(Doñate et al. 2008). Using the Matricel plug model of angiogenesis and
the Lewis lung carcinoma model of tumor growth, studies have shown a U-
Hormesis can help the ailing pharmaceutical industry
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TABLE 1. U-Shaped Dose Response Curves Are Seen With Neuroprotective Agents Acting By
Various Mechanisms 
Agent Mechanism Reference
Nimodipine L-type - Ca2+ channel antagonist Kawaguchi et al. 1999
NAAG Glutamate precursor Lu et al. 2000
Ebselen Antioxidant & Anti-inflammatory Takasago et al. 1997
L-NAME NOS inhibitor Margaill et al. 1997
Nicotinamide NAD+ precursor, PARP inhibitor Ayoub et al. 1999
BW619C89 Glutamate release inhibitor Leach et al. 1993
DPQ PARP inhibitor Takahashi et al. 1997
Progesterone Reproductive hormone (steroid) Chen et al. 1999
MDL 28170 Calpain inhibitor Markgraf et al. 1998
PNQX AMPA (glutamate) receptor antagonist Schielke et al. 1999
Dextrorphan NMDA antagonist Du et al. 1996
Heparin Anti-coagulant Zhao et al. 2001
Aspirin Anti-platelet Maynard et al. 1998
Thioredoxin Anti-apoptotic agent Andoh et al. 2002
GP-683 Adenosine kinase inhibitor Tatlisumak et al. 1998
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shaped dose-response with 1 to 10 mg/kg, but not higher or lower doses
being optimal ATN-161. Interestingly, a biomarker of the anti-angiogenic
action using levels of viable circulating endothelial cells identified by flow
cytometry also exhibited the hormetic response within the same dose
range and can therefore be used to identify optimal dosing in the clinic.
The potential mechanisms of action proposed by Doñate and colleagues
(Doñate et al. 2008) for the hormetic response included a crossover of
drug action from antagonist to agonist due to a lower affinity receptor,
down-regulation of receptors for a particular ligand after exposure satura-
tion and an up-regulation of clearance mechanisms at high concentra-
tions of ligand that feedback to modulate the drug activity.
3. CHALLENGES FOR THE PHARMACEUTICAL INDUSTRY
The pharmaceutical industry is currently facing a variety of hurdles
which may be positively impacted by hormesis, even if in the short term
the concept may require adjustments. Some of these include:
1. A lack of preclinical systems that accurately predict clinical outcomes
(e.g., toxicity and therapeutic efficacy)
2. A high failure rate at all stages of research and development (R&D),
some of which is due to
a. Inappropriate target – during the Discovery phase
b. Toxicity – during the Preclinical phase
c. Lack of efficacy – during the Clinical phase
3. Long R&D timelines from bench to bedside and associated increas-
ing costs
4. Added hurdles of regulatory agencies/health authorities and payers
(e.g., health insurers, health management organizations, Medicare/
Medicaid)
The pharmaceutical industry has responded to these challenges in
part by at least two ways:
1. Trying to reduce the R&D time and costs by sampling large (e.g., over
1 million) chemical libraries, but
a. Assumptions are made such as linear or threshold concentration-
response relationships
b. In vitro - narrow concentration ranges are examined or a wide
range is tested, but sampling many concentrations is reduced or
unrepresentative of the targeted effect
c. In vivo – the same as above for doses, duration or population
sampling of studies tested in animals and humans, i.e., either
narrow ranges or few samples are tested
K. I. Maynard
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2. Focusing R&D on novel mechanisms, molecularly targeted drugs, bi-
ologics and first-in-class molecules, sometimes using advancing tech-
nologies such as computer-assisted models with added risks, which
could result in termination of projects at later and more costly stages
of R&D
Many of these challenges could be positively affected if it is under-
stood that hormesis:
1. Is found widely across many areas of biomedical science and clinical
medicine, thus assumptions of linear and threshold drug-response re-
lationships should not be made
2. Pertains not only to toxicity, but also to efficacy
3. Requires comprehensive sampling of data for successful characteriza-
tion of drug effects, in vitro and in vivo
4. FDA: PHARMACEUTICAL GUIDELINES AND FINDINGS
The Food and Drug Administration (FDA) has dose-response guide-
lines for the pharmaceutical industry to support drug registration
(International Conference on Harmonization (ICH)-E4, November
1994). In this guidance, various points are made which are particularly
critical in the light of hormesis and are excerpted below:
1. Identify reasonable, response-guided titration steps, and the interval
at which they should be taken, again with appropriate adjustments for
patient characteristics. These steps would be based either on the
shape of the typical individual’s dose-effect curves (for both desirable
and undesirable effects) .... and the time needed to detect a change
in these effects
2. Dose-response data for both beneficial and undesirable effects may
provide information that allows approval of a range of doses that
encompass an appropriate benefit-to-risk ratio. A well-controlled,
dose-response study is also a study that can serve as primary evidence
of effectiveness
3. Several dose levels are needed, at least two in addition to placebo, but
in general, study of more than the minimum number of doses is
desirable. A single dose level of drug versus placebo allows a test of
the null hypothesis of no difference between drug and placebo, but
cannot define the dose-response relationship. Similarly, although a
linear relationship can be derived from the response to two active
doses (without placebo), this approximation is usually not sufficient-
ly informative. Study designs usually should emphasize elucidation of
the dose-response function, not individual pair-wise comparisons
Hormesis can help the ailing pharmaceutical industry
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4. Dose-response data should be explored for possible differences in
subsets based on demographic characteristics, such as age, gender, or
race
It has been documented that between the period of 1980 and 1999, 1
in 5 drugs approved underwent significant post-approval dose adjust-
ments by the FDA. Of these cases, 20% had the dose increased and 80%
had the dose decreased (Cross et al. 2002).
In the light of hormesis, careful adherence to these guidelines could
lead to fewer post-approval adjustments. More importantly, it may also
result in a more successful R&D process leading to increased drug
approvals, rather than missed opportunities due to unclearly character-
ized safety, toxicity and efficacy due to potential hormetic effects.
5. HORMESIS: PROVIDING SOLUTIONS IN THE R&D PROCESS
5.1 Discovery – High Through-put Screening
High through-put screening (HTS) is a process in which a large num-
ber of compounds can be tested in cellular and biochemical assays con-
ducted in an automated fashion using large commercial machines capa-
ble of screening e.g., 1,536 and 2,080 wells per plate. The data can pro-
vide statistical hit-identification/confirmation, IC50 profiling, secondary
testing, structural verification of the hit compounds and structure activi-
ty relationship (SAR) information. Thus, typically large libraries of com-
pounds can be screened against drug targets automatically and rapidly
(e.g., receptors) therefore saving time. The focus of using HTS can there-
fore also be used to focus on the thorough elucidation of a full concen-
tration-response curve for each compound being tested, so that any
potential hormetic responses which are now known to be very common
can be discovered, rather than only examining many thousands of com-
pounds with few data points for each so that many compounds can be
tested. Therefore, the range and sampling of data can be increased to
provide a more thorough understanding of the safety, toxicity and effica-
cy of each compound tested.
5.2 Preclinical – Microdosing/Phase 0
Microdosing (as it is called in Europe) or Phase 0 (as it is called in the
USA) studies drug behavior in humans at ultra-low (100 µg) doses unlike-
ly to produce whole-body effects, but allows the study of cellular respons-
es. It helps to predict if a potential drug is viable for phase I testing and
is aimed at reducing animal testing and non-viable drugs early in clinical
development. As written by Graul (2008), “Microdosing also directly address-
es the ethical problems of administering full human doses of a drug or biologic to
healthy volunteers based only on available animal and in vitro data, as well as the
K. I. Maynard
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extreme inaccuracy of predicting humans doses based on animal data, as has been
the standard procedure until now.”
Ultra-low doses are unlikely to produce whole-body effects, but it
allows the study of cellular responses and as such, can be used to improve
our understanding of human safety, toxicity and efficacy. However, one of
the challenges of microdosing is that there might also be non-linearity or
hormesis in extrapolating between a microdose and therapeutic dose
observed in terms of pharmacokinetics and pharmacodynamics (Lappin
and Garner 2008).
Thus, microdosing can be used in the light of hormesis to focus on
obtaining thorough data related to the therapeutic index or margin of
safety by not assuming that (a) the highest dose tolerable is the most effi-
cacious dose and (b) that massive doses are the most toxic. Toxicity or
efficacy may also be seen at lower, rather than higher doses as is readily
seen in hormetic-type responses. It may also help in alleviating the chal-
lenge that despite the fact that receptors may often be highly homologous
across species, animal models of toxicity and disease are frequently not
highly predictive of the clinical outcome in humans.
If re-focused, therefore, the concept of micro-dosing can be used to
save time and money in drug R&D by eliminating testing large amounts
of compounds in toxicity and efficacy animal models by testing micro-
doses directly in humans.
5.3 Phase I – Pharmacometrics
Pharmacometrics is an emerging science that quantifies drug, disease
and trial information to aid efficient drug development and/or regula-
tory decisions. Drug models describe the relationship between exposure
(or pharmacokinetics [PK]), response (or pharmacodynamics [PD]) for
both desired and undesired effects, and individual patient characteristics.
The typical focus of pharmacometrics has been on drug models, also
referred to by terms such as: concentration-effect, dose-response, PKPD
relationships.
The single-most important strength of such analyses is its ability to
integrate knowledge across the development program with regard to the
compounds, and biology.
Dose-response data should be explored for possible differences in
subsets based on demographic characteristics, such as age, gender, or
race as suggested in the FDA guidance.
5.4 Phase II/III – Adaptive Trial Design
Adaptive trial design (ATD) is defined as a study design that includes
a sequence of interim analyses to enable modification of the course of the
clinical trial dynamically (e.g., used by Drug Monitoring Committees
Hormesis can help the ailing pharmaceutical industry
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(DMCs) to stop trials early due to overwhelming evidence of efficacy.
Possible adaptation of late phase clinical trials includes sample size re-esti-
mation by dropping or adding treatment arms (e.g., different doses),
therefore enabling the thorough examination of many doses in a clinical
study (Phillips and Du Mond 2007). Although the complexity of an adap-
tive trial will be higher than a traditional one, it permits multiple objec-
tives to be addressed in a single trial, e.g., identifying the dose-range as
well as the patient population likely to get the maximum drug benefit,
whilst potentially reducing the overall costs. Currently, there is a draft
guideline from the FDA, and their Critical Path Opportunities highlights
ATD as one way of speeding up drug development while reducing costs.
6. CONCLUSION
Hormesis is found not only in biochemistry, radiation biology and
toxicology, but there are many examples of hormesis across a wide range
of biomedical science and clinical medicine. The concept of hormesis
could help the pharmaceutical industry address major concerns, even
though short-term it could add to its challenges, which we have tried to
rectify by reducing R&D timelines and costs via reducing the amount of
data obtained.
Having understood the significant role that hormesis plays in R&D, it
requires a major change in our mindset to focus more on providing more
comprehensive datasets with regard to safety and efficacy all along the
R&D process. In the long-term, this will provide more and better quality
drugs. The use of existing techniques, tools and resources can be used to
our advantage to help ensure that drugs with better safety and efficacy do
not necessarily require major additional R&D costs, but rather carefully
re-allocated resources.
A re-examination of our past failures is needed, since it is likely that
many compounds in R&D were stopped, for example, not because the
target was incorrect or the mechanism invalid, but simply because we
chose the wrong dose assuming a linear or sigmoidal
concentration/dose-response relationship for safety, toxicity or efficacy.
Based on what we understand of hormesis to date, we need to:
1. Define the concentration-response relationship thoroughly in vitro
a. Do not assume a linear or sigmoidal concentration-response rela-
tionship
b. Keep in mind J-shaped, U-shaped or bell-shaped concentration
relationships
2. Identify optimal, not maximal concentrations/doses by sampling
often and over broad test ranges, not only in the early stages in drug
Discovery, but throughout the entire R&D process
K. I. Maynard
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3. Define the therapeutic index by comprehensively characterizing the
safety and efficacy dose responses, and not assuming that the highest
doses lead to greater toxicity or that the maximal tolerated dose is
equivalent to the optimal dose having maximal efficacy.
Ultimately, drug R&D is about science, medicine and creating drugs
to help people. Consequently, although this article has focused on the
impact of hormesis on the pharmaceutical industry, it also applies to aca-
demic research and the elucidation of basic mechanisms of action at the
molecular, cellular and systemic levels.
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